- Home
- PMVP vs ASMB Comparison
PMVP vs ASMB Comparison
Compare PMVP & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- ASMB
- Stock Information
- Founded
- PMVP 2013
- ASMB 2005
- Country
- PMVP United States
- ASMB United States
- Employees
- PMVP N/A
- ASMB N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- ASMB Health Care
- Exchange
- PMVP Nasdaq
- ASMB Nasdaq
- Market Cap
- PMVP 55.1M
- ASMB 139.8M
- IPO Year
- PMVP 2020
- ASMB 2010
- Fundamental
- Price
- PMVP $1.25
- ASMB $18.75
- Analyst Decision
- PMVP Strong Buy
- ASMB Strong Buy
- Analyst Count
- PMVP 1
- ASMB 3
- Target Price
- PMVP $5.00
- ASMB $33.00
- AVG Volume (30 Days)
- PMVP 230.0K
- ASMB 43.5K
- Earning Date
- PMVP 08-07-2025
- ASMB 08-07-2025
- Dividend Yield
- PMVP N/A
- ASMB N/A
- EPS Growth
- PMVP N/A
- ASMB N/A
- EPS
- PMVP N/A
- ASMB N/A
- Revenue
- PMVP N/A
- ASMB $32,154,000.00
- Revenue This Year
- PMVP N/A
- ASMB $0.04
- Revenue Next Year
- PMVP N/A
- ASMB N/A
- P/E Ratio
- PMVP N/A
- ASMB N/A
- Revenue Growth
- PMVP N/A
- ASMB 148.33
- 52 Week Low
- PMVP $0.81
- ASMB $7.75
- 52 Week High
- PMVP $1.82
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- PMVP 64.21
- ASMB 65.84
- Support Level
- PMVP $0.96
- ASMB $18.01
- Resistance Level
- PMVP $1.36
- ASMB $18.99
- Average True Range (ATR)
- PMVP 0.09
- ASMB 0.84
- MACD
- PMVP 0.01
- ASMB -0.05
- Stochastic Oscillator
- PMVP 72.22
- ASMB 84.42
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.